Zurueck zur Suche

Reporte zur Charge F5XN2

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

21Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
KY 3 TX 3 CO 2 CA 2 FL 2 NC 1 MI 1 PA 1 AZ 1 WA 1 OR 1 IL 1

VAERS 1470314

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge f5xn2

moderat
Staat
NC
Alter
58,0
Geschlecht
F
Eingang
14.07.2021
Impfdatum
13.07.2021
Beginn
13.07.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injected limb mobility decreased Limb discomfort Myalgia

Symptomtext

Patient self reported feeling the needle entering her muscle and feeling the Shingrix vaccine being injected into her muscle at the time of vaccination. She reported intense, sore muscle pain in vaccinated arm 2 to 3 hours later, including a feeling of "heavy arm" and couldn't raise her arm above her shoulder. Patient self administered Tylenol and heat compresses and stated that the heat seemed to make it worse but the Tylenol seemed to help. She took her usual prescription of Meloxicam 7.5mg 2 tablets at bedtime and stated the following morning 7/14/21 that her arm felt much better and she had better range of motion than yesterday but still not normal. There is no redness or swelling noted by the patient. Discussed side effect of Shingrix with patient and advised to use cold compresses and seek medical attention if the condition becomes worse or if it remains after 2-3 days from vaccination date.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injected limb mobility decreased
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Mitral valve prolapse, seasonal allergies and arthritis
Vorgeschichte
Arthritis, mitral valve prolapse, seasonal allergies
Andere Medikamente
Meloxicam 7.5 mg every evening at bedtime.
Allergien
-
Vorherige Impfungen
-

VAERS 1292418

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

moderat
Staat
-
Alter
68,0
Geschlecht
M
Eingang
06.05.2021
Impfdatum
30.04.2021
Beginn
02.05.2021
Tage bis Beginn
2,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Computerised tomogram Dyspnoea Influenza like illness Neck pain Pain Painful respiration Sleep disorder

Symptomtext

PATIENT REPORTED FEELING FLU LIKE SYMPOTOMS DAY AFTER INJECTION WHICH WAS EXPECTED. HOWEVER STARTING SUNDAY EVENING HE BEGAN TO HAVE PAIN IN HIS LEFT AREA OF HIS NECK. THAT PAIN THEN BEGAN TO RADIATE DOWN TO HIS LEFT SIDE. THE PAIN BEGAN TO GET MORE INTENSE TO WHERE MONDAY EVENING HE WAS HAVING DIFFICULTY TAKING A DEEP BREATH. MONDAY NIGHT HE WAS UNABLE TO SLEEP DUE TO PAIN AND SHORTNESS OF BREATH. TUESDAY MORNING HE CONTACTED DOCTOR AND THEY SENT HIM FOR CT SCAN. THE SCAN SHOWED A PULMONARY EMBOLISM IN HIS RIGHT LUNG WITH EFFUSION SHOWING IN LEFT LUNG. THE ONLY THING DIFFERENT PATINET DID DURING THIS TIME IS GET THE SHINGRIX VACCINE. DOCTOR THEN PUT PATIENT ON ELIQUIS FOR TREATMENT.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dyspnoea
Hospital-Tage
-
Labordaten
CT
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1041921

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

moderat
Staat
CO
Alter
67,0
Geschlecht
F
Eingang
19.02.2021
Impfdatum
12.02.2021
Beginn
19.02.2021
Tage bis Beginn
7,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja
Dyspnoea Nausea Pain

Symptomtext

Approximately 10 minutes after receiving vaccine patient began filling nauseous. Later that evening patient went to hospital because she thought she was having a heart attack. Entire left side of body was in pain and she was having a hard time breathing.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dyspnoea
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
Shingrix dose 1 on 10/20/2020. age 66. Felt severe flu-like symptoms and was in bed for 4 days.

VAERS 953866

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

moderat
Staat
MI
Alter
56,0
Geschlecht
F
Eingang
18.01.2021
Impfdatum
15.01.2021
Beginn
15.01.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / UN
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Dyspnoea Injection site erythema Pain in extremity Pyrexia

Symptomtext

Pt called pharmacy 1/18/21 to report sore arm the day of injection and new developing redness below injection site. Pt stated arm pain was so significant she left work to go home. Pt denied any other symptoms -fever, shortness of breath, swelling. RPh advised patient to use cool compresses and tylenol for pain and to keep arm moving.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dyspnoea
Hospital-Tage
-
Labordaten
NA
Aktuelle Erkrankungen
NA
Vorgeschichte
hypertension, diabetes
Andere Medikamente
Arimidex 1 mg QD, Januvia 100 mg QD, Losartan 100 QD, Glyburide 5 mg 2 c breakfast + 1 c dinner.
Allergien
iodine
Vorherige Impfungen
-

VAERS 946174

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

moderat
Staat
CA
Alter
67,0
Geschlecht
F
Eingang
15.01.2021
Impfdatum
12.01.2021
Beginn
12.01.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Fatigue Headache Injection site pain Palpitations Pruritus Rash Urticaria

Symptomtext

Patient reports pain at the injection site lasting from 01/12/21 at time of administration until the morning of 01/14/21. Patient reports heart palpitations during the evening of 01/13/21 and hives/rash that developed on 01/13/21 starting on the upper back and has now spread to abdomen and both armpits. Patient took Benadryl on 01/14/21 around 8pm and itching/sensitivity is lessened. Patient reports fatigue on 01/13/21. Patient reports headache on 01/12/21 which subsided with the use of acetaminophen. Patient states headache returned on 01/13/21 to a lesser degree and resolved on its own. Patient denies continued heart palpitations.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Palpitations
Hospital-Tage
-
Labordaten
NA
Aktuelle Erkrankungen
-
Vorgeschichte
HYPOTHYROIDISM
Andere Medikamente
Levothyroxine 75 MCG
Allergien
SULFONAMIDE ANTIBIOTICS
Vorherige Impfungen
-

VAERS 1325825

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
FL
Alter
72,0
Geschlecht
F
Eingang
18.05.2021
Impfdatum
03.05.2021
Beginn
03.05.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Headache Immediate post-injection reaction Inappropriate schedule of product administration Injection site erythema Injection site inflammation Skin warm

Symptomtext

a round (approximately 2.5 inches in diameter) area of inflammation / at the injection site; redness at the injection site; skin was warm to touch; also experienced a headache; first dose of Shingrix April 5, 2021 / on May 3, 2021 / received the second vaccine; This case was reported by a consumer via call center representative and described the occurrence of injection site inflammation in a 72-year-old female patient who received Herpes zoster (Shingrix) (batch number F5XN2, expiry date 8th October 2022) for prophylaxis. Concomitant products included Herpes zoster (Shingrix). On 3rd May 2021, the patient received the 2nd dose of Shingrix (intramuscular). On 3rd May 2021, immediately after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced injection site inflammation, injection site erythema, skin warm, headache and drug dose administration interval too short. On 7th May 2021, the outcome of the injection site inflammation was recovering/resolving. On an unknown date, the outcome of the injection site erythema and skin warm were recovering/resolving and the outcome of the headache was not recovered/not resolved and the outcome of the drug dose administration interval too short was unknown. It was unknown if the reporter considered the injection site inflammation, injection site erythema, skin warm and headache to be related to Shingrix. Additional information was provided as follows: On 5th April 2021, the patient received 1st dose of Shingrix. The patient was instructed to return to receive 2nd dose of shingrix and the patient received 2nd dose of Shingrix, less than the recommended interval, which led to shortening of vaccination schedule. Immediately after receiving 2nd dose, the patient noticed a round (approximately 2.5 inches in diameter) area of inflammation and redness at the injection site. The skin was warm to touch. Those symptoms had improved. On the same day, she also experienced a headache and continued till the reporting date. The reporter consented to follow up via email as well as with her HCP (health care professional).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Headache
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1258574

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
CA
Alter
50,0
Geschlecht
F
Eingang
26.04.2021
Impfdatum
14.04.2021
Beginn
15.04.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Chills Headache Injection site erythema Injection site warmth Pain

Symptomtext

2 inch redness and warmth on left arm where vaccine was administered headache, chills, body aches Tylenol 500mg 2 tablets as needed

Weitere VAERSDATA-Felder
Praegender Schweregrund
Chills
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
wrist pain, hip pain
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 1140251

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
TX
Alter
81,0
Geschlecht
F
Eingang
27.03.2021
Impfdatum
23.03.2021
Beginn
24.03.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
SYR / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Abdominal pain upper Arthralgia Chills Fatigue Headache Injection site inflammation Injection site pain Nausea

Symptomtext

Nausea, stomach pain, joint pain, chills, headache, fatigue, sore and inflamed injection site.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Abdominal pain upper
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
Lupus, EPI
Andere Medikamente
Prednisone, Hydroxychloroquine, Levothyroxine, Triamterene, Zanaflex, Zenpep, fish oil, vitamin D3, calcium, cranberry, biotin, PreserVision, melatonin,
Allergien
None
Vorherige Impfungen
-

VAERS 1118358

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
FL
Alter
52,0
Geschlecht
M
Eingang
20.03.2021
Impfdatum
19.03.2021
Beginn
19.03.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Fatigue Headache Pain in extremity Pyrexia

Symptomtext

Immediate fatigue, moderate arm soreness, then developed 100.0 fever that persists into Day 2, and unresponsive to 2X extra strength tylenol. Severe headache.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Fatigue
Hospital-Tage
-
Labordaten
None.
Aktuelle Erkrankungen
COVID-19 vaccination January 25 and February 15 (Pfizer)--never had COVID-19 no illness.
Vorgeschichte
Migraines, hypertension, coronary artery disease, coronary artery stent placement, asthma, sciatic neuropathy, barrett esophagus/esophageal reflux, hyperlipidemia, Cranial Plate (at 7 years old), former smoker (stopped 2005), carpal tunnel syndrome
Andere Medikamente
Atorvastatin 80mg, Lisinopril-HCTZ 20-25mg, Montelukast Sod 10mg, Nifedipine ER 90mg, Aimovig 140mg/ml (1xmonthly), Diazepam 2mg, Lisinopril 20mg (PM), low dose aspirin, CoQ10, Multivitamin
Allergien
NKA, NKFA, NKDA
Vorherige Impfungen
-

VAERS 1055105

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
CO
Alter
64,0
Geschlecht
F
Eingang
25.02.2021
Impfdatum
15.01.2021
Beginn
15.01.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Anal incontinence Breast pain Defaecation urgency Nipple pain

Symptomtext

Patient stated at time of administration she felt the injection go into her breast, nipple, and areola. She stated she was shopping and felt she couldn't hold her bowels and accidentally defecated in the aisle of the store. She says she has lasting nausea and sudden urges to defecate.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Breast pain
Hospital-Tage
-
Labordaten
none to my knowledge
Aktuelle Erkrankungen
unknown
Vorgeschichte
unknown
Andere Medikamente
acyclovir 400mg
Allergien
penicillins
Vorherige Impfungen
-

VAERS 1017146

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge f5xn2

mild
Staat
PA
Alter
84,0
Geschlecht
F
Eingang
09.02.2021
Impfdatum
08.02.2021
Beginn
09.02.2021
Tage bis Beginn
1,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Pyrexia

Symptomtext

Pt had complained of fever

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pyrexia
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
hypercholesterolemia, depression
Andere Medikamente
Pt said she had a fever
Allergien
none
Vorherige Impfungen
-

VAERS 966450

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
AZ
Alter
70,0
Geschlecht
F
Eingang
22.01.2021
Impfdatum
20.01.2021
Beginn
22.01.2021
Tage bis Beginn
2,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Erythema Injection site erythema Injection site swelling Injection site warmth Musculoskeletal discomfort Peripheral swelling Pruritus

Symptomtext

redness, swelling at injection site, heat, itching on neck, arm and redness swelling on the inside of the elbow joint

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
none at this time
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
align pro biotic laxatives blood pressure anxiety
Allergien
no known allergies
Vorherige Impfungen
-

VAERS 956673

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
KY
Alter
62,0
Geschlecht
F
Eingang
19.01.2021
Impfdatum
13.01.2021
Beginn
13.01.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site nodule Injection site pain Injection site swelling

Symptomtext

Marble-sized knot at injection site. Redness around injection site and swelling/pain around injection site.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 950641

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge f5xn2

mild
Staat
WA
Alter
70,0
Geschlecht
F
Eingang
16.01.2021
Impfdatum
13.01.2021
Beginn
15.01.2021
Tage bis Beginn
2,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site rash Pain in extremity

Symptomtext

patient noticed round 'rash' in left armpit on Friday 1/15/2021, it's just an outline of a circle patient's arm was sore locally for a couple days but nothing else presented, including itching, dryness, muscle aches, fever, or any other body symptoms.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site rash
Hospital-Tage
-
Labordaten
none she stated she was calling her physician if it progressed by Monday I also asked to keep us informed, and she consented
Aktuelle Erkrankungen
none known
Vorgeschichte
none known
Andere Medikamente
not known
Allergien
no known allergies
Vorherige Impfungen
-

VAERS 931994

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

mild
Staat
OR
Alter
50,0
Geschlecht
F
Eingang
09.01.2021
Impfdatum
08.01.2021
Beginn
08.01.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Rash Urticaria

Symptomtext

Hives and rash over torso and spreading

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash
Hospital-Tage
-
Labordaten
None reported
Aktuelle Erkrankungen
none reported
Vorgeschichte
none reported
Andere Medikamente
Tramadol ER 100mg; Cyclobenzaprine 10mg; Estradiol 0.5mg; Trazodone 100mg; Buspirone 15mg; Gabapentin 600mg; Ibuprofen 800mg; Alendronate 70mg; Acyclovir 400mg
Allergien
penicillin, metronidazole, soy, sulfa
Vorherige Impfungen
-

VAERS 1628073

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

gering
Staat
KY
Alter
75,0
Geschlecht
M
Eingang
24.08.2021
Impfdatum
23.08.2021
Beginn
23.08.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Blood pressure increased Epistaxis

Symptomtext

Blood pressure elevated outside of normal (~130/80) to ~147/90. Patient also had a nose bleed that was difficult to stop.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Blood pressure increased
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
None provided
Vorgeschichte
None provided
Andere Medikamente
Unsure
Allergien
None provided
Vorherige Impfungen
-

VAERS 1380605

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

gering
Staat
TX
Alter
89,0
Geschlecht
F
Eingang
08.06.2021
Impfdatum
29.05.2021
Beginn
29.05.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

administration of the second dose after 2 weeks of receiving the first dose / first dose / on 5/13/2021 /second dose on 5/29/2021; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 89-year-old female patient who received Herpes zoster (Shingrix) (batch number F5XN2, expiry date 8th October 2022) for prophylaxis. Concomitant products included Herpes zoster (Shingrix). On 29th May 2021, the patient received the 2nd dose of Shingrix. On 29th May 2021, unknown after receiving Shingrix and 16 days after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown. Additional details were reported as follows: The patient received 2nd dose less than 2 month apart from the 1st dose, which led to shortening of vaccination schedule. No further event was reported. The health care professional consented to follow-up

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1368025

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

gering
Staat
TX
Alter
89,0
Geschlecht
F
Eingang
02.06.2021
Impfdatum
29.05.2021
Beginn
29.05.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Unevaluable event

Symptomtext

Patient has not reported any signs or symptoms of side effects since vaccine was given.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
Infection
Vorgeschichte
Mental disorder, mood disorder, thyroid disorder, high blood pressure, high cholesterol
Andere Medikamente
Primidone, escitalopram, simvastatin, sertraline, rivastigmine, oxybutynin, lisinopril-hctz, levothyroxine, mirtazapine, memantine
Allergien
No known allergies
Vorherige Impfungen
-

VAERS 1288621

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

gering
Staat
IL
Alter
55,0
Geschlecht
F
Eingang
05.05.2021
Impfdatum
29.04.2021
Beginn
29.04.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

Second dose / on April 39th 2021 / first dose was / on March 12th 2021; This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 55-year-old female patient who received Herpes zoster (Shingrix) (batch number F5XN2, expiry date 8th October 2022) for prophylaxis. Concomitant products included Herpes zoster (Shingrix). On 29th April 2021, the patient received the 2nd dose of Shingrix. On 29th April 2021, unknown after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown. Additional information was provided as follows: The patient received 1st dose of Shingrix on 12 March 2021. The nurse reported that the patient received 2nd dose of Shingrix, less than recommended interval, which led to shortening of vaccination schedule. The reporter did not consent to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
Shingrix
Allergien
-
Vorherige Impfungen
-

VAERS 1172473

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge f5xn2

gering
Staat
KS
Alter
51,0
Geschlecht
F
Eingang
06.04.2021
Impfdatum
05.04.2021
Beginn
05.04.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Inappropriate schedule of product administration No adverse event

Symptomtext

Wasn't aware that I was in 14 days of patient's second Covid-19 vaccine. That was given on 3/30/21. Pt was unconcerned, followed up with patient today and she feels fine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
none.
Aktuelle Erkrankungen
no known
Vorgeschichte
depression
Andere Medikamente
sertraline
Allergien
no known
Vorherige Impfungen
-

VAERS 1044673

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge F5XN2

gering
Staat
KY
Alter
51,0
Geschlecht
M
Eingang
21.02.2021
Impfdatum
18.02.2021
Beginn
18.02.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Lymphadenopathy

Symptomtext

Patient reported a swollen lymph node after receiving the Shingrix vaccine

Weitere VAERSDATA-Felder
Praegender Schweregrund
Lymphadenopathy
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-